Nanoparticle/Engineered Bacteria Based Triple-Strategy Delivery System for Enhanced Hepatocellular Carcinoma Cancer Therapy

References

• Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63(5):844–855. doi:10.1136/gutjnl-2013-306627
   PubMed Web of Science ®Google Scholar
• Okuda K. Hepatocellular carcinoma - history, current status and perspectives. Digest Liver Dis. 2002;34(9):613–616. doi:10.1016/S1590-8658(02)80200-67
   Web of Science ®Google Scholar
• Singh AK, Kumar R, Pandey AK. Hepatocellular carcinoma: causes, mechanism of progression and biomarkers. Curr Chem Genom Transl Med. 2018;12:9–26. doi:10.2174/2213988501812010009
   PubMedGoogle Scholar
• Kong H, Ju E, Yi K, et al. Advanced nanotheranostics of CRISPR/Cas for viral hepatitis and hepatocellular carcinoma. Adv Sci. 2021;8(24):e2102051. doi:10.1002/advs.202102051
   Web of Science ®Google Scholar
• Karagiannakis DS. Systemic treatment in intermediate stage (Barcelona Clinic Liver Cancer-B) hepatocellular carcinoma. Cancers. 2023;16(1). doi:10.3390/cancers16010051
   PubMed Web of Science ®Google Scholar
• Zheng K, Wang X. Techniques and status of hepatic arterial infusion chemotherapy for primary hepatobiliary cancers. Ther Adv Med Oncol. 2024;16:1758–8359. doi:10.1177/17588359231225040
   Web of Science ®Google Scholar
• Yu YC, Mao YM, Chen CW, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int. 2017;11(3):221–241. doi:10.1007/s12072-017-9793-2
   PubMed Web of Science ®Google Scholar
• Yi K, Kong H, Zheng C, et al. A LIGHTFUL nanomedicine overcomes EGFR-mediated drug resistance for enhanced tyrosine-kinase-inhibitor-based hepatocellular carcinoma therapy. Biomaterials. 2023;302:122349. doi:10.1016/j.biomaterials.2023.122349
   PubMed Web of Science ®Google Scholar
• Noori M, Jafari-Raddani F, Davoodi-Moghaddam Z, et al. Immune checkpoint inhibitors in gastrointestinal malignancies: an Umbrella review. Cancer Cell Int. 2024;24(1):10. doi:10.1186/s12935-023-03183-3
   PubMed Web of Science ®Google Scholar
• Zhu HD, Li HL, Huang MS, et al. Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduct Target Ther. 2023;8(1):58. doi:10.1038/s41392-022-01235-0
   PubMed Web of Science ®Google Scholar
• Pinter M, Jain RK, Duda DG. The current landscape of immune checkpoint blockade in hepatocellular carcinoma. JAMA Oncol. 2021;7(1):113–123. doi:10.1001/jamaoncol.2020.3381
   PubMed Web of Science ®Google Scholar
• Escartin A, Sapisochin G, Bilbao I, et al. Recurrence of hepatocellular carcinoma after liver transplantation. Transplant Proc. 2007;39(7):2308–2310. doi:10.1016/j.transproceed.2007.06.042
   PubMed Web of Science ®Google Scholar
• Bi N, Shedden K, Zheng X, et al. Comparison of the effectiveness of radiofrequency ablation with stereotactic body radiation therapy in Inoperable stage I non-small cell lung cancer: a systemic review and pooled analysis. Int J Radiat Oncol Biol Phys. 2016;95(5):1378–1390. doi:10.1016/j.ijrobp.2016.04.016
   PubMed Web of Science ®Google Scholar
• Schonherr J, Seifert P, Guhne F, et al. Transarterial radioembolization (TARE) in patients with hepatocellular carcinoma: a comparison of palliative with bridging-to-transplant concepts. Cancers. 2024;16(1). doi:10.3390/cancers16010235
   PubMed Web of Science ®Google Scholar
• Xiang C, Shen X, Zeng X, et al. Effect of transarterial chemoembolization as postoperative adjuvant therapy for intermediate stage hepatocellular carcinoma with microvascular invasion: a multicenter cohort study. Int J Surg. 2023;110(1):315–323. doi:10.1097/JS9.0000000000000805
   Web of Science ®Google Scholar
• Zhao Y, Liu J, Xiong Z, et al. Exosome-derived miR-23a-5p inhibits HCC proliferation and angiogenesis by regulating PRDX2 expression: miR-23a-5p/PRDX2 axis in HCC progression. Heliyon. 2024;10(1):e23168. doi:10.1016/j.heliyon.2023.e23168
   PubMed Web of Science ®Google Scholar
• Yang F, Xu GL, Huang JT, et al. Transarterial chemoembolization combined with immune checkpoint inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: efficacy and systemic immune response. Front Immunol. 2022;13:847601. doi:10.3389/fimmu.2022.847601
   PubMed Web of Science ®Google Scholar
• Zhou S, Gravekamp C, Bermudes D, et al. Tumour-targeting bacteria engineered to fight cancer. Nat Rev Cancer. 2018;18(12):727–743. doi:10.1038/s41568-018-0070-z
   PubMed Web of Science ®Google Scholar
• Wang S, Cheng M, Chen CC, et al. Salmonella immunotherapy engineered with highly efficient tumor antigen coating establishes antigen-specific CD8+ T cell immunity and increases in antitumor efficacy with type I interferon combination therapy. Oncoimmunology. 2024;13(1):2298444. doi:10.1080/2162402X.2023.2298444
   PubMed Web of Science ®Google Scholar
• Han ZY, Zhang C, An JX, et al. Metabolic regulation of tumor microenvironment with biohybrid bacterial bioreactor for enhanced cancer chemo‐immunotherapy. Adv Funct Mater. 2023;33:35. doi:10.1002/adfm.202302728
   Web of Science ®Google Scholar
• Zhou T, Wu J, Tang H, et al. Enhancing tumor-specific recognition of programmable synthetic bacterial consortium for precision therapy of colorectal cancer. NPJ Biofilms Microbiomes. 2024;10(1):6. doi:10.1038/s41522-024-00479-8
   PubMed Web of Science ®Google Scholar
• Yu X, Lin C, Yu J, et al. Bioengineered Escherichia coli nissle 1917 for tumour-targeting therapy. Microb Biotechnol. 2020;13(3):629–636. doi:10.1111/1751-7915.13523
   PubMed Web of Science ®Google Scholar
• Siddiqui NA, Ventrola AJ, Hartman AR, et al. An Engineered probiotic platform for cancer epitope-independent targeted radionuclide therapy of solid tumors. Adv Healthc Mater. 2023:e2202870. doi:10.1002/adhm.202202870
   PubMed Web of Science ®Google Scholar
• Liu Y, Lu Y, Ning B. Intravenous delivery of living Listeria monocytogenes elicits gasdmermin-dependent tumor pyroptosis and motivates anti-tumor immune response. ACS Nano. 2022;16(3):4102–4115. doi:10.1021/acsnano.1c09818
   PubMed Web of Science ®Google Scholar
• Curran CS, Rasooly A, He M, et al. Report on the NCI microbial-based cancer therapy conference. Cancer Immunol Res. 2018;6(2):122–126. doi:10.1158/2326-6066.CIR-17-0748
   PubMed Web of Science ®Google Scholar
• Lin Z, Meng F, Ma Y, et al. In situ immunomodulation of tumors with biosynthetic bacteria promote anti-tumor immunity. Bioact Mater. 2024;32:12–27. doi:10.1016/j.bioactmat.2023.09.007
   PubMed Web of Science ®Google Scholar
• Song S, Vuai MS, Zhong M. The role of bacteria in cancer therapy - enemies in the past, but allies at present. Infect Agent Cancer. 2018;13:9. doi:10.1186/s13027-018-0180-y
   PubMed Web of Science ®Google Scholar
• Yang X, Komatsu S, Reghu S, et al. Optically activatable photosynthetic bacteria-based highly tumor specific immunotheranostics. Nano Today. 2021;37:101100. doi:10.1016/j.nantod.2021.101100
   Web of Science ®Google Scholar
• Zhu J, Ke Y, Liu Q, et al. Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy. Nat Commun. 2022;13(1):7466. doi:10.1038/s41467-022-35130-7
   PubMed Web of Science ®Google Scholar
• Savage TM, V. RL, Rae SS, et al. Chemokines expressed by engineered bacteria recruit and orchestrate antitumor immunity. Sci Adv. 2023;9:eadc9436. doi:10.1126/sciadv.adc94
   PubMed Web of Science ®Google Scholar
• Pan P, Dong X, Chen Y, et al. Engineered bacteria for enhanced radiotherapy against breast carcinoma. ACS Nano. 2022;16:801–812. doi:10.1021/acsnano.1c08350
   PubMed Web of Science ®Google Scholar
• Fan JX, Li ZH, Liu XH, et al. Bacteria-mediated tumor therapy utilizing photothermally-controlled TNF-alpha expression via oral administration. Nano Lett. 2018;18(4):2373–2380. doi:10.1021/acs.nanolett.7b05323
   PubMed Web of Science ®Google Scholar
• Canale FP, Basso C, Antonini G, et al. Metabolic modulation of tumours with engineered bacteria for immunotherapy. Nature. 2021;598:662–666. doi:10.1038/s41586-021-04003-2
   PubMed Web of Science ®Google Scholar
• Jia HR, Zhu YX, Liu Y, et al. Direct chemical editing of gram-positive bacterial cell walls via an enzyme-catalyzed oxidative coupling reaction. Exploration. 2022;2(5):20220010. doi:10.1002/EXP.20220010
   Google Scholar
• Chowdhury S, Castro S, Coker C, et al. Programmable bacteria induce durable tumor regression and systemic antitumor immunity. Nat Med. 2019;25(7):1057–1063. doi:10.1038/s41591-019-0498-z
   PubMed Web of Science ®Google Scholar
• Din MO, Danino T, Prindle A, et al. Synchronized cycles of bacterial lysis for in vivo delivery. Nature. 2016;536(7614):81–85. doi:10.1038/nature18930
   PubMed Web of Science ®Google Scholar
• Zhan Y, Zhang Y, Mao C, et al. Improved tumor infiltration and immunomodulation for tumor therapy: a pathway based on tetrahedral framework nucleic acids coupled bacterial nanocells. Nano Lett. 2023;23(1):353–362. doi:10.1021/acs.nanolett.2c03943
   PubMed Web of Science ®Google Scholar
• Guo H, Cao Z, Li J, et al. Integrating bacteria with a ternary combination of photosensitizers for monochromatic irradiation-mediated photoacoustic imaging-guided synergistic photothermal therapy. ACS Nano. 2023;17(5):5059–5071. doi:10.1021/acsnano.3c00032
   PubMed Web of Science ®Google Scholar
• Chen B, Zhang X, Cheng L, et al. Surface programmed bacteria as photo-controlled NO generator for tumor immunological and gas therapy. J Control Release. 2023;353:889–902. doi:10.1016/j.jconrel.2022.12.030
   PubMed Web of Science ®Google Scholar
• Yang M, Chen W, Yang F, et al. Engineered bacteria combined with doxorubicin nanoparticles suppress angiogenesis and metastasis in murine melanoma models. Acta Biomater. 2023;158(1):734–746. doi:10.1016/j.actbio.2022.12.027
   PubMedGoogle Scholar
• Guan X, Guo Z, Wang T, et al. A pH-responsive detachable PEG shielding strategy for gene delivery system in cancer therapy. Biomacromolecules. 2017;18(4):1342–1349. doi:10.1021/acs.biomac.7b00080
   PubMed Web of Science ®Google Scholar
• Xu C, Wang P, Zhang J. Pulmonary codelivery of doxorubicin and siRNA by pH-sensitive nanoparticles for therapy of metastatic lung cancer. Small. 2015;11(34):4321–4333. doi:10.1002/smll.201501034
   PubMed Web of Science ®Google Scholar
• Gupta A, Reizman IM, Reisch CR, et al. Dynamic regulation of metabolic flux in engineered bacteria using a pathway-independent quorum-sensing circuit. Nat Biotechnol. 2017;35(3):273–279. doi:10.1038/nbt.3796
   PubMed Web of Science ®Google Scholar
• Stricker J, Cookson S, Bennett MR, et al. A fast, robust and tunable synthetic gene oscillator. Nature. 2008;456(7221):516–519. doi:10.1038/nature07389
   PubMed Web of Science ®Google Scholar
• Wu S, Liu J, Liu C, et al. Quorum sensing for population-level control of bacteria and potential therapeutic applications. Cellular Mol Life Sci. 2019;77(7):1319–1343. doi:10.1007/s00018-019-03326-8
   PubMed Web of Science ®Google Scholar
• Baicheng Wei JP, Yuan R, et al. Polarization of tumor-associated macrophages by nanoparticle loaded Escherichia coli combined with immunogenic cell death for cancer immunotherapy. Nano Lett. 2021;21(10):4231–4240. doi:10.1021/acs.nanolett.1c00209
   PubMed Web of Science ®Google Scholar
• Lou X, Chen Z, He Z, et al. Bacteria-mediated synergistic cancer therapy: small microbiome has a big hope. Nanomicro Lett. 2021;13(1):37. doi:10.1007/s40820-020-00560-9
   PubMed Web of Science ®Google Scholar
• Chen X, Li P, Luo B, et al. Surface Mineralization of engineered bacterial outer membrane vesicles to enhance tumor photothermal/immunotherapy. ACS Nano. 2024;18(2):1357–1370. doi:10.1021/acsnano.3c05714
   PubMed Web of Science ®Google Scholar
• Hu Q, Wu M, Fang C, et al. Engineering nanoparticle-coated bacteria as oral DNA vaccines for cancer immunotherapy. Nano Lett. 2015;15(4):2732–2739. doi:10.1021/acs.nanolett.5b00570
   PubMed Web of Science ®Google Scholar
• Vincent RL, G. CR, Fangda L, et al. Probiotic-guided CAR-T cells for solid tumor targeting. Science. 2023;382:211–218. doi:10.1126/science.add7034
   PubMed Web of Science ®Google Scholar
• Wang W, Xu H, Ye Q, et al. Systemic immune responses to irradiated tumours via the transport of antigens to the tumour periphery by injected flagellate bacteria. Nat Biomed Eng. 2022;6(1):44–53. doi:10.1038/s41551-021-00834-6
   PubMed Web of Science ®Google Scholar
• Chandradas S, Skillin CB, Frenette CT. Hepatocellular carcinoma: metastatic disease. Int Cancer Metastasis. 2017;163–175. doi:10.1016/B978-0-12-804003-4.00009-8
   Google Scholar
• Liu P, Gou M, Yi T, et al. Efficient inhibition of an intraperitoneal xenograft model of human ovarian cancer by HSulf-1 gene delivered by biodegradable cationic heparin-polyethyleneimine nanogels. Oncol Rep. 2012;27(2):363–370. doi:10.3892/or.2011.1550
   PubMed Web of Science ®Google Scholar
• Li J, Mo ML, Chen Z, et al. HSulf-1 inhibits cell proliferation and invasion in human gastric cancer. Cancer Sci. 2011;102(10):1815–1821. doi:10.1111/j.1349-7006.2011.02024.x
   PubMed Web of Science ®Google Scholar
• Liu S-S, Liu C, Lv X-X, et al. The chemokine CCL1 triggers an AMFR-SPRY1 pathway that promotes differentiation of lung fibroblasts into myofibroblasts and drives pulmonary fibrosis. Immunity. 2021;54(9):2042–2056.e2048. doi:10.1016/j.immuni.2021.06.008
   PubMed Web of Science ®Google Scholar
• Gong X, Wu J, Wen J, et al. Dual-Ligand-Modified Nanoscale Liposomes Loaded with Curcumin and Metformin Inhibit Drug Resistance and Metastasis of Hepatocellular Carcinoma. ACS Appl Nano Mater. 2022;5(5):7063–7077. doi:10.1021/acsanm.2c01027
   Web of Science ®Google Scholar